Drug Search Results
More Filters [+]

Placulumab

Alternative Names: placulumab
Latest Update: 2016-07-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Placulumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Sciatica

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C37247/1083

P2

Completed

Sciatica

2013-03-01

Recent News Events

Date

Type

Title